Orphan Drug Consulting for 340B Covered Entities

Q: Is orphan drug designation a big deal?

This designation is significant because it can qualify a sponsor for tax credits on qualified clinical testing, a waiver of the prescription drug user fee, and potentially seven years of market exclusivity after approval. For a covered entity, it also helps determine whether a drug falls under the 340B orphan drug exclusion for certain hospital types.

Orphan Drug Consulting for 340B Covered Entities

Orphan drug rules move fast. Few hospitals have the bandwidth to track every designation change on their own. That is where orphan drug consulting comes in. 340B Orphan Drug Solutions works alongside covered entities to sort out which orphan drugs qualify for 340B pricing, which ones fall under a manufacturer's discretionary discount, and where the gaps in your current process are costing you money. If you need orphan drug experts who live in this niche every day, you are in the right place.

Pharmacy directors and 340B coordinators are already stretched thin managing split billing and annual recertification. They are also occupied with oversight of contract pharmacies. Adding orphan drug tracking on top of that workload usually means it gets reviewed once a quarter, if at all. A dedicated orphan drug consulting partner closes that gap without asking your team to take on more work.

What is Orphan Drug Consulting?

Orphan drug consulting is specialized guidance that helps covered entities manage the intersection of orphan drug designations and the 340B Drug Pricing Program.

An orphan drug is any drug or biologic granted orphan status by the Food and Drug Administration (FDA). The FDA designates this status to drugs that treat, diagnose, or prevent a rare disease, generally one affecting fewer than 200,000 people in the United States.

Under Section 340B(e) of the Public Health Service Act, certain covered entity types cannot claim mandatory 340B pricing for orphan drugs. This makes expert review essential before assuming a drug is out of reach.

Orphan Drug Consulting Services

340B Orphan Drug Solutions offers a full range of pharmacy consulting and 340B compliance services. These services are built around orphan drugs specifically, not general 340B oversight.

Our key services include:

Orphan drug designation tracking against the FDA Office of Orphan Products Development database
Manufacturer discretionary pricing monitoring, updated as terms change
340B eligibility review by covered entity type. These entities include Disproportionate Share Hospitals (DSHs), critical access hospitals (CAHs), and freestanding cancer hospitals
Split billing software configuration support to capture every eligible discount
Custom quarterly reporting built around your facility's own drug formulary
Audit preparation and recordkeeping guidance for orphan drug purchases

Every engagement is built around your facility's existing workflow. We do not ask your team to adopt a new system from scratch.

Who This Orphan Drug Consulting Service is For

This service fits hospitals and health systems that already participate in the 340B Drug Pricing Program and want a closer look at their orphan drug spend specifically.

Our consulting service tends to be the right fit for:

CAHs and sole community hospitals (SCHs) navigating the orphan drug exclusion
DSHs with a growing specialty and infusion pharmacy footprint
Children's hospitals managing a high volume of rare disease patients
Pharmacy directors who need clearer reporting to bring to finance and compliance teams

If your facility is unsure whether it even qualifies as a covered entity, a 340B Program Compliance review is usually the right starting point before any orphan drug-specific work begins.

Why Work With 340B Consultants Who Specialize in Orphan Drugs

General 340B consultants often treat orphan drugs as a footnote. That gap is exactly why a narrower focus matters.

Here is why you should work with 340B consultants who specialize in orphan drugs:

Frequent Changes in Orphan Drug Pricing

Orphan drug pricing changes quarterly, manufacturer by manufacturer. A generalist consulting team may not catch a new discretionary discount until months after it takes effect. Thus, working with orphan drug experts means someone is watching those changes full time.

Requirement for Pattern Recognition

A dedicated team also brings pattern recognition. After years of reviewing orphan drug designations across many hospital types, an experienced consultant can flag a likely savings opportunity faster than a team encountering it for the first time.

340B Orphan Drug Solutions is led by a pharmacist who has:

More than a decade of orphan drug-specific experience
A longer career in healthcare
A track record of helping hospitals identify substantial orphan drug savings they had been missing.

That depth of experience is the difference between a generic compliance checklist and guidance that reflects what is actually happening in the orphan drug market right now.

340B Consulting Process Timeline

Most engagements follow a consistent path from first conversation to ongoing quarterly support.

Here is how our consulting process timeline looks:

Stage	What Happens
Week 1	Initial compliance review call and formulary intake
Weeks 2 to 3	Orphan drug designation audit against your current purchasing data
Weeks 3 to 4	Manufacturer discretionary pricing research and gap analysis
Week 5	Custom report delivered with savings opportunities and compliance notes
Ongoing	Quarterly updates as designations and manufacturer pricing change

340B Compliance Assessment Checklist

Before any recommendations are made, we start every engagement with a compliance assessment. This step matters because two hospitals with similar formularies can have very different orphan drug exposure depending on their entity type and purchasing history.

Here is what an ideal review should cover:

Checklist Item	Purpose
Covered entity type confirmation	Determines which orphan drug exclusion rules apply to your facility
OPAIS registration accuracy	Confirms outpatient facilities and contract pharmacies are properly listed
Orphan drug designation status by NDC	Flags which drugs on your formulary currently hold orphan status
Manufacturer discretionary pricing terms	Identifies where voluntary discounts are available beyond the statutory minimum
Split billing configuration	Checks that your software correctly separates 340B and non-340 B claims
Recordkeeping and audit trail	Verifies documentation is ready if a manufacturer or federal audit occurs

Common 340B Consulting Challenges & Solutions

Covered entities tend to run into the same few obstacles, quarter after quarter, regardless of size or region.

Here is how orphan drug consulting typically addresses those obstacles:

Challenge	Consulting Solution
Manual tracking of orphan drug status takes hours each quarter	Automated tracking against the FDA orphan drug database, reviewed and reported to your team
Uncertainty over which entity type rules apply	Entity-specific eligibility review tied to current statute and HRSA guidance
Missed discretionary manufacturer discounts	Ongoing manufacturer pricing monitoring with proactive alerts
Difficulty preparing for audits	Structured recordkeeping support and documentation review before audits happen
Limited internal pharmacy staff bandwidth	Outsourced quarterly reporting that plugs into your existing workflow

340B Consulting Benefits Comparison

It helps to see the difference between managing orphan drug tracking internally and bringing in dedicated support.

Approach	Typical Outcome
Handled internally, part-time	Hours spent each quarter cross-checking designations manually, higher risk of missed discounts
General 340B consulting, not orphan specific	Broad compliance support, but orphan drug pricing changes may be reviewed less frequently
Dedicated orphan drug consulting	Focused quarterly tracking, discretionary pricing alerts, and audit-ready documentation

Q1. What is an orphan drug company?

An orphan drug company is a pharmaceutical or biotech sponsor that develops drugs or biologics specifically for rare diseases. These drugs are generally for diseases affecting less than 200,000 people in the United States.

These sponsors submit designation requests to the FDA Office of Orphan Products Development. They do this to qualify their product for orphan status and its related incentives.

Q2. Is orphan drug designation a big deal?

This designation is a huge deal because:

● It qualifies a sponsor for tax credits on qualified clinical testing

● It makes the designated company eligible for a waiver of the prescription drug user fee.

● Also, designated companies potentially receive seven years of market exclusivity after approval.

● For a covered entity, it also determines whether a drug falls under the 340B orphan drug exclusion for certain hospital types.

Q3. What is the top-selling orphan drug?

The specific top seller changes from year to year as new drugs are approved, and older ones lose exclusivity. What is consistent is the therapeutic pattern. A federal review of FDA orphan drug approvals from 2008 to 2017 found that more than half were concentrated in oncology and hematology. These are the fields where many of the highest revenue orphan drugs tend to fall.

Q4. What is the FDA orphan drug exemption?

Any sponsor developing a drug or biologic to treat, diagnose, or prevent a rare disease can request orphan drug designation, provided the drug and the disease meet the criteria set out under the Orphan Drug Act.

Q5. Who pays for orphan drug development?

In most cases, the sponsor, meaning the pharmaceutical or biotech company, funds the bulk of development costs. The costs are often offset by orphan drug incentives such as tax credits and user fee waivers.

The FDA also runs its own Orphan Products Grants Program. The program is a congressionally funded program that awards grants directly to clinical investigators to help fund trials and natural history studies for rare disease products.

Q6. How do I submit an orphan drug designation?

Sponsors can submit an orphan drug designation request to the FDA Office of Orphan Products Development in one of three ways:

● Through the CDER NextGen portal

● By emailing the required information to [email protected], or

● By mail to the Office of Orphan Products Development in Silver Spring, Maryland.

The FDA 4035 form is designed to help sponsors organize the required content before submission.

Talk to an Orphan Drug Consulting Team That Knows This Space

Orphan drug rules will keep changing, and your covered entity should not have to absorb that risk alone. 340B Orphan Drug Solutions brings orphan drug expertise, pharmacy consulting, and 340B compliance services together in one team, so nothing falls through the cracks between quarterly updates. Schedule your compliance review today and find out what your facility may be missing.

Disclaimer

This content is provided for general informational purposes only and does not constitute legal, regulatory, reimbursement, or financial advice. All savings figures, examples, and calculations on this page are illustrative estimates, not guarantees. Actual 340B and orphan drug savings vary based on manufacturer pricing decisions, patient population, drug mix, and 340B compliance status. Covered entities should confirm current requirements directly with HRSA's Office of Pharmacy Affairs and consult qualified counsel before making compliance or purchasing decisions.